IDEXX Q2 revenue $861M +4% reported; EPS $1.56 -33%; cuts FY2022 guidance

IDEXX LABORATORIES INC /DE

2022-Q2 EPS reported $3.82 revenue$1,697,095,000

Revenue $861M, up 4% reported and 6.5% organic; CAG Diagnostics recurring revenue +4% reported, +7% organic.
EPS $1.56, down 33% as reported, including $0.72 impact from $80M discrete R&D investments.
Record Q2 premium instrument placements up 18% YoY; global installed base +15%.
Updated FY2022 revenue guidance $3,305-$3,385M (3%-5.5% reported, 5.5%-8% organic); EPS $7.77-$8.05.
U.S. same-store clinical visits declined 3% in Q2 vs +13% prior year; diagnostics revenue +6% same-store.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.